75 citations,
March 2014 in “Journal of Investigative Dermatology”
Aging mice have slower hair regeneration due to changes in signal balance, but the environment, not stem cell loss, controls this, suggesting treatments could focus on environmental factors.
A treatment containing WntandFollistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
The conversation discusses the complexity of hair loss causes, suggesting that DHT sensitivity alone doesn't fully explain it. Treatments mentioned include finasteride and dutasteride.